Omniose

Omniose is a private, pre-clinical biotech founded in 2021 and based in Cambridge, MA, focused on revolutionizing conjugate vaccine development. The company's core innovation is a proprietary bioconjugation platform that uses engineered E. coli cells to simultaneously produce polysaccharide antigens and carrier proteins and enzymatically link them, a process designed to be simpler and more precise than traditional chemical methods. This 'Omniose' (all sugars) platform seeks to unlock vaccines for a broader spectrum of bacterial pathogens that have been difficult to target with existing conjugate vaccine technology. The company is in the early stages of building its pipeline against serious bacterial threats.

Proprietary bioconjugation platform using engineered E. coli cells to simultaneously produce bacterial polysaccharide antigens and carrier proteins and enzymatically link them in a single, simplified process. Aims to enable conjugate vaccines for a broader range of bacterial targets.

Competes with large vaccine companies (GSK, Pfizer, Sanofi) with established conjugate vaccine portfolios and chemical conjugation expertise, as well as other biotechs exploring alternative conjugation methods (e.g., synthetic biology, other enzymatic platforms). Differentiation hinges on proving superior simplicity, breadth, and quality of its bioconjugation approach.